Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Cerebrovascular Accident
47%
Statin (Protein)
41%
Brain Hemorrhage
36%
Clopidogrel
34%
Brain Ischemia
33%
Transient Ischemic Attack
32%
Acute Heart Infarction
31%
Bevacizumab
27%
Antipsychotic
27%
Proton Pump Inhibitor
27%
Ticagrelor
27%
Crohn's Disease
27%
Antibiotics
20%
Biological Product
19%
Histamine H2 Receptor Antagonist
19%
Medication Error
18%
Retrospective Study
18%
Acetylsalicylic Acid
17%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Wet Macular Degeneration
14%
End Stage Renal Disease
13%
Retina Detachment
13%
Bloodstream Infection
13%
Chronic Obstructive Lung Disease
13%
Cetuximab
13%
Prescription Medication
13%
Community Pharmacy
13%
COX-2 Inhibitor
13%
Metastatic Colorectal Cancer
13%
Retrolental Fibroplasia
13%
Clostridium Difficile Infection
13%
Endocrine Therapy
13%
Acute Coronary Syndrome
13%
Cardiovascular Agent
13%
Magnesium Stearate
13%
Pulmonary Hypertension
13%
Venous Thromboembolism
13%
Viral Respiratory Tract Infection
13%
Coughing
13%
Hypotension
13%
Febuxostat
13%
Systolic Heart Failure
13%
Stress Ulcer
13%
Sildenafil
13%
Cation Exchange Resin
13%
Allopurinol
13%
Atrial Fibrillation
13%
Thiazolidinedione
13%
Kidney Disease
13%
Keyphrases
National Cohort Study
27%
Population-based Cohort Study
15%
Neovascular Age-related Macular Degeneration (nAMD)
14%
Statin Adherence
13%
Short-term Mortality
13%
Pay-for-performance
13%
Recurrent Venous Thromboembolism
13%
Crohn's Disease
13%
Self-controlled Case Series Study
13%
Oral Fluoroquinolones
13%
Get With The Guidelines
13%
Mild Chronic Obstructive Pulmonary Disease
13%
Oral Antidiabetic Medication
13%
Access to Medicines
13%
Medication Prescription
13%
Common Reference
13%
Community Pharmacy
13%
Chronic Medication
13%
Taiwan
13%
Dosing Recommendations
13%
Newly Onset
13%
Suboptimal Outcome
13%
Lower Gastrointestinal Tract
13%
Cardiovascular Drugs
13%
Histamine-2 Receptor Antagonists (H2RA)
13%
H2-receptor Antagonists
13%
Cough
13%
Intravitreal Bevacizumab
13%
Drug Use Pattern
13%
Bevacizumab Therapy
13%
Magnesium Stearate
13%
Viral Respiratory Infections
13%
Cumulative Recurrence Rate
13%
Spatial Panel Data Model
13%
Primary Tumor Resection
13%
Ion Exchange Resin
13%
Aspirin
13%
Febuxostat
13%
Risk Management Strategies
13%
Pharmacological Thromboprophylaxis
13%
Surrogate Measures
13%
Registry Linkage
13%
Home Time
13%
History of Disease
13%
CHADS2 Score
13%
Systolic Heart Failure
13%
Stress Ulcer Prophylaxis
13%
Ischemic Outcomes
13%
Death Records
13%
Gastrointestinal Injury
13%
Medicine and Dentistry
Cohort Analysis
29%
Proton-Pump Inhibitor
27%
Hazard Ratio
24%
H2 Antagonist
19%
Venous Thromboembolism
13%
Community-Acquired Pneumonia
13%
Clostridium Difficile Infection
13%
Diabetic Retinopathy
13%
Metastatic Colorectal Cancer
13%
Disease Exacerbation
13%
End Stage Renal Disease
13%
Wet Macular Degeneration
13%
Pneumococcus Vaccine
13%
Cancer Surgery
13%
Coughing
13%
Retrospective Study
13%
Viral Respiratory Tract Infection
13%
Patient with Crohn's Disease
13%
Cyclooxygenase 2 Inhibitor
13%
Bevacizumab
13%
Chemoprophylaxis
13%
Clopidogrel
13%
Pulmonary Hypertension
13%
Systolic Heart Failure
13%
CHADS2 Score
13%
Cetuximab
13%
Thromboprophylaxis
13%
Stress Ulcer
13%
Cation Exchange Resin
13%
Febuxostat
13%
Retreatment
13%
Primary Tumor
13%
Nephropathy
13%
Sildenafil
13%
Crohn's Disease
10%
Biological Product
10%
Retrospective Cohort Study
10%
Disease Severity
9%
Histamine H2 Receptor
8%
Chronic Kidney Disease
7%
Biological Therapy
6%
Cardiovascular System
6%
Treatment Duration
6%
Cumulative Incidence
5%
